Phase III Clinical Trial COMPETE with n.c.a. 177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET compared to mTOR inhibitor Everolimus.
PRRT as treatment option for cancers like neuroendocrine tumors. See a practicing physician and two patients talking about their experience.
Find challenging opportunities within the ITM Group. Our employees are a key success factor, as each individual contributes to the overall success of the Company through his/her work ...